论文部分内容阅读
目的:评价甲硝唑与克林霉素联用治疗细菌性阴道炎患者的临床疗效及其安全性。方法:选取2014年12月—2016年11月期间收治的细菌性阴道炎患者84例临床资料,将其随机分为单一组与联合组(每组42例);单一组患者给予甲硝唑治疗,联合组患者在单一组基础上加用克林霉素治疗,比较两组患者治疗后的总有效率、复发与不良反应的发生率。结果:治疗后联合组患者的总有效率为80.95%高于单一组为54.76%(P<0.05),复发率为7.14%高于单一组为21.43%(P<0.05);两组患者用药期间不良反应的发生率经组间比较其差异无统计学意义(P<0.05)。结论:甲硝唑与克林霉素联用于治疗细菌性阴道炎患者的疗效优于单用甲硝唑,降低了复发率和不良反应的发生率。
Objective: To evaluate the clinical efficacy and safety of metronidazole combined with clindamycin in the treatment of bacterial vaginosis. Methods: A total of 84 patients with bacterial vaginosis admitted from December 2014 to November 2016 were selected and randomly divided into single group and combined group (42 cases in each group). Patients in a single group were treated with metronidazole . The combination group was treated with clindamycin on the basis of a single group. The total effective rate, recurrence rate and adverse reaction rate after treatment were compared between the two groups. Results: The total effective rate in the combined group after treatment was 80.95%, which was significantly higher than that in the single group (54.76%, P <0.05). The recurrence rate was 7.14% in the combined group and 21.43% (P <0.05) in the single group. The incidence of adverse reactions was no significant difference between groups (P <0.05). Conclusion: Metronidazole combined with clindamycin in the treatment of bacterial vaginosis is superior to metronidazole alone, reducing the recurrence rate and the incidence of adverse reactions.